FDA approves Cabometyx for differentiated thyroid cancer
The agency cleared cabozantinib for patients 12 and older whose disease progressed after VEGFR-targeted therapy and who cannot receive or do not respond to radioactive iodine.
The FDA approved cabozantinib, sold as Cabometyx by Exelixis, Inc., for a new indication in differentiated thyroid cancer. The approval covers patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.1
The approval expands the drug's use to a pediatric and adult population defined by prior treatment history, specifically those who have already received a VEGFR-targeted therapy and seen their cancer advance, and who either cannot be treated with radioactive iodine or whose disease does not respond to it.
The FDA's announcement does not include additional details on trial data, dosing regimens, or further regulatory steps beyond stating the approval itself.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.